Novo Nordisk's Wegovy Pediatric Trial: Obesity Reversed in 40% of Participants
nashnova research
Novo Nordisk reported that 40.4% of obese children aged 6–12 on Wegovy saw their BMI fall out of the obesity range after 68 weeks — versus zero in the placebo group — marking the drug's first completed trial in younger children and giving Novo a temporary lead over Eli Lilly in paediatric obesity.
How was this trial designed?
Subjects were obese children aged 6 to 12, treated for 68 weeks with once-weekly Wegovy injections at doses well below the adult maximum.
The drug group also followed a low-calorie diet and increased physical activity; the control group received diet-and-exercise guidance only, with no drug.
This means → the comparison was not "drug vs. doing nothing" but "drug + lifestyle vs. lifestyle alone" — a fairly strict control design.
What does the 40% reversal number actually show?
About two in five children on Wegovy saw their BMI — body-mass index, a weight-to-height ratio used to classify obesity — drop to the normal or overweight range, no longer classified as obese.
In the placebo group, not a single child met that threshold.
In plain terms = diet and exercise alone moved zero children out of obesity; adding the drug got nearly half there. That gap is the drug's net effect.
Novo said the drug's overall safety and tolerability were consistent with earlier paediatric and adult trials.
Why does the children's obesity market matter?
U.S. childhood obesity is at an all-time high: roughly one in five children and adolescents are obese.
Their complications — including heart disease and diabetes — often do not surface until adulthood.
This means → intervening in childhood could, in theory, break the chain from "obese child" to "chronically ill adult." The potential patient pool is large.
How far behind is Eli Lilly?
Lilly's obesity drugs have not yet completed a comparable trial in children. Novo holds a temporary lead in the paediatric indication.
In plain terms = the two companies are neck-and-neck in the adult weight-loss market, but on this new front — children — Novo has the clinical data first.
Whether the paediatric indication translates into actual revenue still depends on regulatory approval and market-access negotiations.
Why didn't the stock move?
After the announcement, Novo's Copenhagen-listed shares trimmed an earlier decline and ended roughly flat.
The stock is down about 8% year-to-date, weighed down by several earlier pipeline trial failures.
This reflects a market that is currently more focused on Novo's broader pipeline setbacks than on any single paediatric win — one positive readout is not yet enough to reset that sentiment.
市场有风险，内容仅供研究参考，不构成投资建议。